Clinical trials: Conversion
Overweight, Hypercholesterolemia
Supplementation of Alpha-linolenic Acid (ALA)-Rich Oil in Humans
The objective of this study is to investigate the accumulation of n-3 LC-PUFA (EPA, DPA and DHA) in human lipids by oral supplementation of ALA-rich linseed oil.
- Trial name
- ALA_KK (NCT01317290)
- Testing
- n-3 PUFA free olive oil, linseed oil
- Where
- Germany
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- University of Jena
Kidney Transplantation, Chronic Kidney Failure
Early Conversion From Tacrolimus to Efalizumab Maintenance Therapy in Kidney Transplant Recipients
The toxicity of calcineurin inhibitors(CNI)is a major factor limiting the success of renal transplantation. This protocol aims to replace the calcineurin inhibitor, tacrolimus, with efalizumab early after transplantation in…
- Trial name
- NCT00472082
- Testing
- efalizumab
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Emory University
ARDS, NRDS
Acute Respiratory Distress Syndrome(ARDS) in Neonates
Acute respiratory distress syndrome in neonates has been defined in 2015. Earlier identification and successful intervention into the potential pregnancy associated risk factors for the conversion from NRDS to ARDS is one of the…
- Trial name
- NCT03227289
- Testing
- Stayed in NRDS, Converted to ARDS
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Anemia, Dialysis-Dependent Chronic Kidney Disease
Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Participants With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)
A multicenter, randomized, open-label, active-controlled Phase 3 study for the correction or maintenance treatment of anemia in participants with incident dialysis-dependent chronic kidney disease (DD-CKD).
- Trial name
- NCT02865850
- Testing
- Vadadustat, Darbepoetin alfa
- Where
- 118 sites in United States, Argentina and 9 more
- Volunteers
- 369 people
- Sponsor
- Akebia Therapeutics
Gastric Cancer, Gastric Adenocarcinoma
Conversion Therapy of Sintilimab in Combination With Fruquintinib and Chemotherapy Versus Sintilimab and Chemotherpay in Stage IV Gastric Cancer
This is a multicenter, randomized, open-label, phase 2 clinical study aiming to evaluate the feasibility and efficacy of sintilimab (PD-1 inhibitor) in combination of fruquintinib and chemotherapy (S-1 plus nab-paclitaxel) versus…
- Conditions
- Gastric Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT06454435
- Testing
- Sintilimab + Fruquinitinib + S-1 plus nab-paclitaxel, Sintilimab + S-1 plus nab-paclitaxel
- Where
- China
- Volunteers
- 158 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Kidney Transplantation, Pediatric Patients
Conversion of Prograf to Advagraf in Pediatric Renal Transplant Recipients
This study was designed to compare the pharmacokinetics of Prograf and Advagraf in stable pediatric kidney transplant recipients.
- Conditions
- Kidney Transplantation, Pediatric Patients, Maintenance With Tacrolimus
- Trial name
- NCT01476488
- Testing
- tacrolimus
- Where
- South Korea
- Sponsor
- Seoul National University Hospital
Renal Transplant, Conversion
Early Pharmacological and Immune Monitoring After Conversion to Belatacept in Renal Transplant Patients
Single-center, prospective, translational, clinical-biological, multidisciplinary study
- Trial name
- EPIMAC-BELA (NCT05632523)
- Testing
- Blood sample, urinary sample
- Where
- France
- Volunteers
- 10 people
- Sponsor
- University Hospital, Tours
Esophageal Squamous Cell Carcinoma (ESCC), Locally Advanced Unresectable Esophageal Cancer
Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma
This is a Phase II, open-label, single-arm, multicenter study evaluating the safety and efficacy of combining Tislelizumab with induction chemoradiotherapy (CRT), followed by conversion surgery, in patients with locally advanced…
- Trial name
- NCT07039162
- Testing
- Tislelizumab, Paclitaxel, Cisplatin
- Where
- 8 sites in Taiwan
- Volunteers
- 45 people
- Sponsor
- Ming-Yu Lien
Educational Problems
PBP vs Traditional Training: the T-REC Trial
This randomized controlled trial aims to compare the effectiveness of traditional training approach to training with the proficiency-based progression (PBP) approach for teaching the technical skills (TS) and non-technical skills…
- Trial name
- T-REC (NCT06147128)
- Testing
- Emergency scenario in a simulated setting where open conversion is necessary due to vessel injury during robotic surgery on a dry lab model
- Where
- Belgium
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Orsi Academy
Metastatic Colorectal Cancer
A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
FC-6 is a Phase II, multi-center clinical trial for patients with unresectable, wild-type K-RAS, colorectal cancer with metastases confined to the liver.
- Trial name
- NCT00803647
- Testing
- cetuximab, 5-FU, oxaliplatin
- Where
- 23 sites in United States
- Volunteers
- 20 people
- Sponsor
- NSABP Foundation Inc
Gastric Cancer (GC), AFP Gastric or Gastroesophageal Junction Adenocarcinoma
Efficacy of Sintilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastric/Gastroesophageal Junction Adenocarcinoma
Alpha-fetoprotein-producing gastric cancer (AFP-positive gastric cancer, AFP-GC), a rare and highly aggressive subtype of gastric cancer, accounts for 1.3% to 15% of all gastric cancer cases.
- Trial name
- NCT07515625
- Testing
- Sintilimab, Bevacizumab, Oxaliplatin
- Volunteers
- 46 people
- Sponsor
- Fudan University
Gastric Cancer, HIPEC, Anti-PD-1 Antibody Camrelizumab (SHR-1210), Chemotherapy and Surgery
HIPEC Combined With Camrelizumab, Paclitaxel and S-1 for Conversion Therapy in Patients With Advanced Gastric Cancer With Peritoneal Metastasis
There is no currently available treatment for peritoneal metastasis of gastric cancer. Hyperthermic intraperitoneal chemotherapy (HIPEC) can not only maintain the high concentration of drugs in the abdominal cavity, but also…
- Trial name
- NCT04889768
- Testing
- HIPEC, anti-PD-1 antibody Camrelizumab (SHR-1210), Chemotherapy and Surgery
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Zhejiang Cancer Hospital
Spinal Cord Injury, Chronic Spinal Cord Injury
First-in-Human Clinical Trial of STUP-001, an In Vivo Direct Cell Conversion Gene Therapy for AIS-A/B Chronic Spinal Cord Injury
This study aim to investigate the safety and exploratory efficacy of STUP-001 which is AAV-based spinal cord injury investigational product.
- Trial name
- STUP-001 (NCT06922890)
- Testing
- STUP-001
- Where
- South Korea
- Volunteers
- 9 people
- Sponsor
- Yonsei University
Gastric Cancer
The Study of Conversion Surgery for Apatinib in Combination With SOX for Patients With Unresectable Gastric Cancer
This is a Prospective，Single-center，Single-arm，Open-label exploratory clinical trial evaluating the efficacy and safety of Conversion Surgery for Apatinib plus SOX for patients with unresectable gastric cancer.
- Trial name
- NCT03007446
- Testing
- Apatinib, Oxaliplatin, S-1
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Chinese PLA General Hospital
Esophagus Cancer
Neoadjuvant Comprehensive Treatment for Unresectable Esophageal Cancer
Patients diagnosed with locally advanced esophageal squamous cell carcinoma (ESCC) that is deemed unresectable face a bleak prognosis.
- Trial name
- NEXUS-2 (NCT06430658)
- Testing
- Tislelizumab (BGB-A317) with chemoradiotherapy
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Renal Transplant Patients at High-risk for Skin Cancer
Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol
Transplant recipients have a high risk to develop skin malignancies. This effect depends on the one hand on the immunosuppressive drugs themselves and relates on the other hand on the dosage.
- Trial name
- PROSKIN (NCT01797315)
- Testing
- Sirolimus
- Volunteers
- 40 people
- Sponsor
- University Hospital of Berlin
Multiple Sclerosis, RRMS
Multicenter Prospective Study Analyzing the Occurrence of Multiple Sclerosis Relapses Without Radiological Evidence: Myth or Reality?
The MYTH-MS study is a multicenter prospective study investigating the occurrence of clinical relapses in patients with relapsing-remitting multiple sclerosis (RRMS) in the absence of radiological activity on MRI.
- Conditions
- Multiple Sclerosis, RRMS, Multiple Sclerosis (MS) - Relapsing-remitting
- Trial name
- MYTH-MS (NCT07545889)
- Testing
- Early Cerebro-spinal MRI, Biomarker Assessment, Clinical and Neuropsychological Evaluations
- Where
- 8 sites in France
- Volunteers
- 136 people
- Sponsor
- University Hospital, Strasbourg, France
Gait Disorders, Neurologic, Gait Disorders in Old Age
ExerG: Video Game-based Physical Cognitive Training for Patients: a Usability Study
Video game-based training programs, in the following referred to as "exergames" are an innovative digital training approach to simultaneously train physical and cognitive functions and increase training motivation for various…
- Conditions
- Gait Disorders, Neurologic, Gait Disorders in Old Age, Gait Disorder, Sensorimotor, Balance; Distorted
- Trial name
- ExerGetic (NCT05967078)
- Testing
- ExerG
- Where
- Switzerland
- Volunteers
- 20 people
- Sponsor
- Frank Behrendt
Clinical High-risk
Develop a Psychosis Risk Calculator for Chinese Mental Health Servises
This project will use the collected clinical and biological information of high-risk groups, use embedded computer chips, and use big data background analysis system to comprehensively evaluate the risk of high-risk groups, and…
- Trial name
- NCT04509778
- Testing
- routine clinical treatment
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shanghai Mental Health Center
Gastric Cancer
Conversion Therapy of Camrelizumab Plus Chemoradiotherapy in Participants With Initial Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
This is a study of Camrelizumab in Combination With concurrent radiotherapy and SOX for Initial Unresectable or potentially resectable proximal Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.
- Trial name
- NCT04631757
- Testing
- Camrelizumab + SOX + Radiotherapy
- Volunteers
- 33 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital